SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy’s may launch 3 new drugs in the US and to issue bonus debentures worth Rs 520 crore

10 Mar 2011 Evaluate

Dr Reddy’s Laboratories may launch three new drugs in the US market next fiscal after the settlement of disputes with foreign players over the rights to two of them and a favourable court ruling in a third case.Dr Reddy’s may launch Rivastigmine ($132m), an anti-mild-to-moderate Alzheimer’s drug, Desloratadine, ($229 mn) used to treat allergies and Pseudoephedrine, a nasal/sinus decongestant.

In 2008, the company entered into a settlement agreement with Novartis Pharma that involves a stipulation of dismissal of lawsuits filed in the United States relating to Rivastigmine capsules sold under the trade name Exelon.Dr Reddy’s inked agreements in 2009 with Schering and Sepracor of the USA, which will allow the Indian drug-maker to manufacture and market generic versions of Desloratadine, starting 2012. Similarly, Dr Reddy’s got a shot in the arm after the US District Court of New Jersey recently cleared decks for the launch of the generic version of Allegra-D 24 in US. The revenues from generic sales in North America stood at $301 million in the last fiscal and $287 million so far this year.

Dr Reddy's Laboratories will issue bonus debentures to its shareholders worth up to Rs 520 crorecrackcrack

Dr. Reddys Lab Share Price

1220.75 -11.50 (-0.93%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×